Trial · NCT03853369
Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection
NCT03853369, Unknown, Sichuan Baili Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection. Trials, record NCT03853369. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03853369
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection
- NCT number
- NCT03853369
- Status
- Unknown
- Enrollment
- 2,000 participants, estimated
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Conditions
- Ventricular Tachycardia, Ventricular Fibrillation
- Interventions
- Nifekalant hydrochloride
- First posted
- 2019-02-25
- Last updated
- 2019-03-14
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The rate of termination / prevention of ventricular tachycardia / ventricular fibrillation attack and relapse. | From the beginning of the administration to 48 hours after the end of the administration. | The efficiency during the treatment and observation periods, including the rate of termination / prevention of ventricular tachycardia / ventricular fibrillation attack and relapse. |
| Secondary | Number of Participants with adverse events | From the beginning of the administration to 48 hours after the end of the administration. | Number of Participants with Tdp, ventricular tachycardia or ventricular fibrillation. |
| Secondary | Heart rate | 3 days before the beginning of the administration to 48 hours after the end of the administration. | The subjects' heart rate will be recorded and the abnormalities will be analyzed. |
| Secondary | The survival rate | 30 days after the end of administration. | The 30 days survival rate. |
| Secondary | Blood pressure | 3 days before the beginning of the administration to 48 hours after the end of the administration. | Both systolic and diastolic pressures will be assessed during the study period. |
| Secondary | Respiratory rate | 3 days before the beginning of the administration to 48 hours after the end of the administration. | The respiratory status of all subjects will be recorded the incidence of abnormalities will be calculated. |
| Secondary | Body temperature | 3 days before the beginning of the administration to 48 hours after the end of the administration. | The subjects' temperatures will be recorded and the abnormalities will be analyzed. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03853369
GET https://conductscience.org/api/trials/v1/NCT03853369/registered